On Monday, Canaccord Genuity (TSX:CF) updated its financial model for GH Research PLC (NASDAQ:GHRS), leading to a slight increase in the company's price target. The firm now sees the stock reaching $31.00, up from the previous target of $30.00, while reiterating a Buy rating for the shares.
The adjustment comes after GH Research reported its first-quarter results for 2024. Canaccord Genuity's analysis includes a 40% probability of approval for GH001, GH Research's therapeutic candidate for treatment-resistant depression (TRD), anticipating a potential market launch in the United States and Europe around 2028.
The firm's peak sales estimates for GH001 have been revised upward to $3.4 billion, factoring in projections for the year 2035, an increase from the $3.0 billion forecast for 2034. Despite the heightened sales expectations, Canaccord Genuity has not made significant changes to its operating expense projections for GH Research.
In their valuation, Canaccord Genuity continues to exclude any potential revenue from off-label uses of GH001 or from GH002, another compound in GH Research's pipeline. The primary driver for the increased price target is the extension of the discounted cash flow (DCF) analysis period from the end of 2024 to mid-2025.
The updated price target reflects Canaccord Genuity's confidence in GH Research's growth prospects, particularly concerning its lead product candidate, GH001, for the treatment of TRD. The firm's analysis suggests continued investor optimism for GH Research's future financial performance.
InvestingPro Insights
Following Canaccord Genuity's updated financial model for GH Research PLC, real-time data from InvestingPro provides a deeper look into the company's current financial health. GH Research holds a market capitalization of $607.69 million, indicating a significant presence in its sector. Despite not paying dividends, the company has seen a strong return over the last three months, with a price total return of 53.08%. Moreover, the company has outperformed in the short term, with an 8.65% return over the past week.
InvestingPro Tips highlight that GH Research holds more cash than debt, suggesting a stable financial position, and liquid assets exceed short-term obligations, which may provide some resilience in volatile markets. However, it's worth noting that analysts do not anticipate the company will be profitable this year, and net income is expected to drop. These factors are crucial for investors to consider when evaluating the company's long-term prospects, especially in the context of the optimistic outlook from Canaccord Genuity for GH001's potential market launch.
For those looking to delve further into GH Research's financials and future outlook, InvestingPro offers additional tips that can be accessed at https://www.investing.com/pro/GHRS. To enhance your investing strategy, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 6 more InvestingPro Tips available, investors can gain a comprehensive understanding of GH Research's market position and investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.